ARCHIVES

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

This article is from The Cancer Letter archive.

Vol. 35 No. 15 | April 17, 2009

Download PDF Visit The Full Archive

Related Articles

How Low Can You Go? ODAC Accepts Retrospective Study for Accelerated Approval

September 30, 2011

CPT-11, Gemcitabine Increase Survival Of Pancreatic Cancer

March 29, 2002

Congress Ignores construction Fund Reprogramming

February 18, 1977

Alexion In Collaboration With Netherlands Center.

November 30, 2001

FDA Approves DNA Test For Two Types of HPV

March 27, 2009

Movement To Resolve Patient Care Reimbursement Problems Gains Momentum; NCI Report Adds Fuel

March 17, 1989